BRPI0923480A2 - formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas - Google Patents

formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas

Info

Publication number
BRPI0923480A2
BRPI0923480A2 BRPI0923480A BRPI0923480A BRPI0923480A2 BR PI0923480 A2 BRPI0923480 A2 BR PI0923480A2 BR PI0923480 A BRPI0923480 A BR PI0923480A BR PI0923480 A BRPI0923480 A BR PI0923480A BR PI0923480 A2 BRPI0923480 A2 BR PI0923480A2
Authority
BR
Brazil
Prior art keywords
pyridazin
morpholin
pyrazol
pyrimidin
ethoxy
Prior art date
Application number
BRPI0923480A
Other languages
English (en)
Inventor
Axel Becker
Christoph Saal
Clemens Kuehn
Cristina Donini
Dieter Dorsch
Eva Kriegbaum
Frank Stieber
Oliver Schadt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0923480(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0923480A2 publication Critical patent/BRPI0923480A2/pt
Publication of BRPI0923480B1 publication Critical patent/BRPI0923480B1/pt
Publication of BRPI0923480B8 publication Critical patent/BRPI0923480B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0923480A 2008-12-22 2009-11-24 formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etóxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona, seus processos de fabricação, composição farmacêutica, medicamento, e kit BRPI0923480B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22
EP08022253.2 2008-12-22
PCT/EP2009/008358 WO2010072295A1 (en) 2008-12-22 2009-11-24 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof

Publications (3)

Publication Number Publication Date
BRPI0923480A2 true BRPI0923480A2 (pt) 2016-08-09
BRPI0923480B1 BRPI0923480B1 (pt) 2020-10-13
BRPI0923480B8 BRPI0923480B8 (pt) 2021-05-25

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923480A BRPI0923480B8 (pt) 2008-12-22 2009-11-24 formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etóxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona, seus processos de fabricação, composição farmacêutica, medicamento, e kit

Country Status (31)

Country Link
US (1) US8586599B2 (pt)
EP (1) EP2361250B1 (pt)
JP (2) JP5690741B2 (pt)
KR (1) KR101663335B1 (pt)
CN (1) CN102264729B (pt)
AR (1) AR074686A1 (pt)
AU (1) AU2009331990B2 (pt)
BR (1) BRPI0923480B8 (pt)
CA (1) CA2748218C (pt)
CL (1) CL2011001278A1 (pt)
CO (1) CO6331435A2 (pt)
CY (1) CY1114659T1 (pt)
DK (1) DK2361250T3 (pt)
EA (1) EA019320B1 (pt)
EC (1) ECSP11011219A (pt)
ES (1) ES2434247T3 (pt)
HR (1) HRP20130993T1 (pt)
IL (1) IL213647A (pt)
MX (1) MX2011006682A (pt)
MY (1) MY160526A (pt)
NZ (1) NZ594172A (pt)
PE (1) PE20120016A1 (pt)
PL (1) PL2361250T3 (pt)
PT (1) PT2361250E (pt)
SG (1) SG172128A1 (pt)
SI (1) SI2361250T1 (pt)
SM (1) SMT201300133B (pt)
TW (1) TWI448463B (pt)
UA (1) UA103646C2 (pt)
WO (1) WO2010072295A1 (pt)
ZA (1) ZA201105394B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
US11180480B2 (en) 2017-10-17 2021-11-23 Sensorion Synthesis of 4-aminopyrimidine compounds

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
US20040259863A1 (en) 2001-10-31 2004-12-23 Hans-Michael Eggenweiler Type 4 phosphodiesterase inhibitors and uses thereof
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
JP2011500629A (ja) 2007-10-16 2011-01-06 ノバルティス アーゲー 神経ペプチドｙ２受容体のモジュレーターとしての置換ピペラジンおよびピペリジン
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−０８３
WO2009057827A1 (en) 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
EP2242483B1 (en) 2007-12-21 2013-02-20 Synthon B.V. Raloxifene composition
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101903385B (zh) 2007-12-21 2013-11-06 帕劳制药股份有限公司 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2008340421B2 (en) 2007-12-21 2013-12-19 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CA2709514A1 (en) 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
AR069869A1 (es) 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2323994A1 (en) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
BRPI1013159A2 (pt) 2009-03-30 2015-09-15 Sumitomo Chemical Co Uso de composto de piridazinona para controle de peste artrópode
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
TW201028409A (en) 2010-08-01
WO2010072295A1 (en) 2010-07-01
CL2011001278A1 (es) 2011-09-30
IL213647A0 (en) 2011-07-31
JP2012513417A (ja) 2012-06-14
DK2361250T3 (da) 2013-11-04
PL2361250T3 (pl) 2014-01-31
KR101663335B1 (ko) 2016-10-06
AR074686A1 (es) 2011-02-02
CN102264729B (zh) 2014-03-05
NZ594172A (en) 2013-04-26
US8586599B2 (en) 2013-11-19
CA2748218C (en) 2017-08-29
JP5690741B2 (ja) 2015-03-25
MX2011006682A (es) 2011-07-13
CN102264729A (zh) 2011-11-30
BRPI0923480B8 (pt) 2021-05-25
TWI448463B (zh) 2014-08-11
UA103646C2 (ru) 2013-11-11
EP2361250B1 (en) 2013-08-07
AU2009331990B2 (en) 2016-04-14
US20110257180A1 (en) 2011-10-20
ZA201105394B (en) 2012-03-28
AU2009331990A1 (en) 2011-08-11
CY1114659T1 (el) 2016-10-05
EA019320B1 (ru) 2014-02-28
EA201100973A1 (ru) 2012-01-30
MY160526A (en) 2017-03-15
BRPI0923480B1 (pt) 2020-10-13
EP2361250A1 (en) 2011-08-31
PE20120016A1 (es) 2012-01-24
CA2748218A1 (en) 2010-07-01
CO6331435A2 (es) 2011-10-20
ECSP11011219A (es) 2011-12-30
JP2015028093A (ja) 2015-02-12
JP5860125B2 (ja) 2016-02-16
SI2361250T1 (sl) 2013-12-31
ES2434247T3 (es) 2013-12-16
SG172128A1 (en) 2011-07-28
SMT201300133B (it) 2014-03-07
IL213647A (en) 2013-11-28
HRP20130993T1 (hr) 2013-11-22
HK1164837A1 (en) 2012-09-28
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11

Similar Documents

Publication Publication Date Title
NL301050I2 (nl) Relebactam of het monohydraat ervan
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
CO7071131A2 (es) Formas polimórficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluor-3-fenilquinazolin-4(3h)-ona
HUE053643T2 (hu) (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0808118A2 (pt) Revestimento hidrófilo
BRPI0808105A2 (pt) Revestimento hidrófilo
BRPI0920450A2 (pt) Pirrolobenzodiazepinas
EP2269063A4 (en) PREDICTING THE RISK OF HEAVY UNWANTED DAMAGE EVENTS
BRPI0909367A2 (pt) calçado e método de fabricação do mesmo
EP2638816A4 (en) HOHLE SCHUHSOHLE AND METHOD FOR THEIR PRODUCTION
BRPI0915826A2 (pt) dispositivo de retenção de pino
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
EP2432473A4 (en) PYRAZOLOPYRIMIDINES AND CORRESPONDING HETEROCYCLES AS KINASE INHIBITORS
BRPI0811495A2 (pt) Aplicador de acabamento de piso
LT2313364T (lt) Simetrinio dimetilarginino nustatymo būdai
BRPI0922013A2 (pt) gavetas de refrigerador com acabamento
BRPI0815207A2 (pt) pirimidinas bicíclicas fundidas
BRPI0814512A2 (pt) Aplicador de acabamento de piso
BRPI0816718A2 (pt) Fabricação contínua de poliuretano/poliureias
BRPI0908998A2 (pt) Soluções hidrófilas de poliuretanos
GB0816741D0 (en) Array of aircraft seats - interlocking herringbone
HUE038673T2 (hu) Eljárás nedves kerámia extrudátum külsõ rétege merevségének szabályozására
BRPI0923480A2 (pt) formas polimorficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabricacao das mesmas
BRPI0919511A2 (pt) métodos de redução de células t auxiliares de células b para o tratamento de doenças autoimunes

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2802 DE 17-09-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.